Recent advances in predicting responses to antidepressant treatment

F1000Research

Volumn 6, Issue , 2017, Pages

  Frodl, Thomas ^a  

^a OTTO VON GUERICKE UNIVERSITY   (Germany)

Author keywords

Antidepressant treatment; Depression; EEG; Major depressive disorder; Neuroimaging

Indexed keywords

ANTIDEPRESSANT AGENT; BIOLOGICAL MARKER; MICRORNA; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR;

ACCURACY; BRAIN REGION; DISEASE COURSE; DRUG EFFICACY; EVENT RELATED POTENTIAL; FUNCTIONAL NEUROIMAGING; GENE EXPRESSION; HEMATOLOGICAL PARAMETERS; HUMAN; LONGITUDINAL STUDY; MAJOR DEPRESSION; NERVOUS SYSTEM ELECTROPHYSIOLOGY; OUTCOME ASSESSMENT; PHARMACOGENETICS; PREDICTION; PREDICTIVE VALUE; PROGNOSIS; RECEIVER OPERATING CHARACTERISTIC; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE;

EID: 85019617473     PISSN: 20461402     EISSN: 1759796X     Source Type: Journal    
DOI: 10.12688/f1000research.10300.1     Document Type: Review

References (46)

1. Kessler RC Berglund P Demler O: Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2005;62(6):593-602. 15939837 10.1001/archpsyc.62.6.593
2. Nierenberg AA Fava M Trivedi MH: A comparison of lithium and T 3 augmentation following two failed medication treatments for depression: a STAR*D report. Am J Psychiatry. 2006;163(9):1519-30; quiz 1665. 16946176 10.1176/ajp.2006.163.9.1519
3. Frodl T: MR Neuroimaging of Depression. In: MRI in Psychiatry[Internet]. Heidelberg New York Dordrecht London: Springer;2014;275-287. 10.1007/978-3-642-54542-9_14
4. Mayberg HS Brannan SK Mahurin RK: Cingulate function in depression: a potential predictor of treatment response. Neuroreport. 1997;8(4):1057-61. 9141092
5. Wu J Buchsbaum MS Gillin JC: Prediction of antidepressant effects of sleep deprivation by metabolic rates in the ventral anterior cingulate and medial prefrontal cortex. Am J Psychiatry. 1999;156(8):1149-58. 10450253
6. Mayberg HS Liotti M Brannan SK: Reciprocal limbic-cortical function and negative mood: converging PET findings in depression and normal sadness. Am J Psychiatry. 1999;156(5):675-82. 10327898
7. Goldapple K Segal Z Garson C: Modulation of cortical-limbic pathways in major depression: treatment-specific effects of cognitive behavior therapy. Arch Gen Psychiatry. 2004;61(1):34-41. 14706942 10.1001/archpsyc.61.1.34
8. Brody AL Saxena S Silverman DH: Brain metabolic changes in major depressive disorder from pre- to post-treatment with paroxetine. Psychiatry Res. 1999;91(3):127-39. 10641577 10.1016/S0925-4927(99)00034-7
9. Kennedy SH Evans KR Krüger S: Changes in regional brain glucose metabolism measured with positron emission tomography after paroxetine treatment of major depression. Am J Psychiatry. 2001;158(6):899-905. 11384897 10.1176/appi.ajp.158.6.899
10. Buchsbaum MS Wu J Siegel BV: Effect of sertraline on regional metabolic rate in patients with affective disorder. Biol Psychiatry. 1997;41(1):15-22. 8988791 10.1016/S0006-3223(96)00097-2
11. Brody AL Saxena S Stoessel P: Regional brain metabolic changes in patients with major depression treated with either paroxetine or interpersonal therapy: preliminary findings. Arch Gen Psychiatry. 2001;58(7):631-40. 11448368 10.1001/archpsyc.58.7.631
12. Samson AC Meisenzahl E Scheuerecker J: Brain activation predicts treatment improvement in patients with major depressive disorder. J Psychiatr Res. 2011;45(9):1214-22. 21477817 10.1016/j.jpsychires.2011.03.009
13. Seminowicz DA Mayberg HS McIntosh AR: Limbic-frontal circuitry in major depression: a path modeling metanalysis. Neuroimage. 2004;22(1):409-18. 15110034 10.1016/j.neuroimage.2004.01.015
14. Lisiecka D Meisenzahl E Scheuerecker J: Neural correlates of treatment outcome in major depression. Int J Neuropsychopharmacol. 2011;14(4):521-34. 21205435 10.1017/S1461145710001513
15. Frodl T Scheuerecker J Schoepf V: Different effects of mirtazapine and venlafaxine on brain activation: an open randomized controlled fMRI study. J Clin Psychiatry. 2011;72(4):448-57. 20868630 10.4088/JCP.09m05393blu
16. Fu CH Williams SC Cleare AJ: Neural responses to sad facial expressions in major depression following cognitive behavioral therapy. Biol Psychiatry. 2008;64(6):505-12. 18550030 10.1016/j.biopsych.2008.04.033
17. Siegle GJ Carter CS Thase ME: Use of FMRI to predict recovery from unipolar depression with cognitive behavior therapy. Am J Psychiatry. 2006;163(1):735-8. 16585452 10.1176/appi.ajp.163.4.735
18. Williams LM Korgaonkar MS Song YC: Amygdala Reactivity to Emotional Faces in the Prediction of General and Medication-Specific Responses to Antidepressant Treatment in the Randomized iSPOT-D Trial. Neuropsychopharmacology. 2015;40(10):2398-408. 25824424 10.1038/npp.2015.89 4538354 F1000 Recommendation
19. Frodl T Meisenzahl EM Zetzsche T: Hippocampal and amygdala changes in patients with major depressive disorder and healthy controls during a 1-year follow-up. J Clin Psychiatry. 2004;65(4):492-9. 15119911 10.4088/JCP.v65n0407
20. Redlich R Opel N Grotegerd D: Prediction of Individual Response to Electroconvulsive Therapy via Machine Learning on Structural Magnetic Resonance Imaging Data. JAMA Psychiatry. 2016;73(6):557-64. 27145449 10.1001/jamapsychiatry.2016.0316 F1000 Recommendation
21. Arns M Olbrich S: Personalized Medicine in ADHD and Depression: Use of Pharmaco-EEG. Curr Top Behav Neurosci. 2014;21:345-70. 24615541 10.1007/7854_2014_295 F1000 Recommendation
22. van Dinteren R Arns M Kenemans L: Utility of event-related potentials in predicting antidepressant treatment response: An iSPOT-D report. Eur Neuropsychopharmacol. 2015;25(11):1981-90. 26282359 10.1016/j.euroneuro.2015.07.022 F1000 Recommendation
23. Gallinat J Bottlender R Juckel G: The loudness dependency of the auditory evoked N1/P2-component as a predictor of the acute SSRI response in depression. Psychopharmacology (Berl). 2000;148(4):404-11. 10928314 10.1007/s002130050070
24. Jaworska N Blondeau C Tessier P: Response prediction to antidepressants using scalp and source-localized loudness dependence of auditory evoked potential (LDAEP) slopes. Prog Neuropsychopharmacol Biol Psychiatry. 2013;44:100-7. 23360662 10.1016/j.pnpbp.2013.01.012 3654010
25. Lee BH Park YM Lee SH: Prediction of long-term treatment response to selective serotonin reuptake inhibitors (SSRIs) using scalp and source loudness dependence of auditory evoked potentials (LDAEP) analysis in patients with major depressive disorder. Int J Mol Sci. 2015;16(3):6251-65. 25794285 10.3390/ijms16036251 4394530 F1000 Recommendation
26. Oakes TR Pizzagalli DA Hendrick AM: Functional coupling of simultaneous electrical and metabolic activity in the human brain. Hum Brain Mapp. 2004;21(4):257-70. 15038007 10.1002/hbm.20004
27. Pizzagalli D Pascual-Marqui RD Nitschke JB: Anterior cingulate activity as a predictor of degree of treatment response in major depression: evidence from brain electrical tomography analysis. Am J Psychiatry. 2001;158(3):405-15. 11229981 10.1176/appi.ajp.158.3.405
28. Mulert C Juckel G Brunnmeier M: Rostral anterior cingulate cortex activity in the theta band predicts response to antidepressive medication. Clin EEG Neurosci. 2007;38(2):78-81. 17515172 10.1177/155005940703800209
29. Korb AS Hunter AM Cook IA: Rostral anterior cingulate cortex activity and early symptom improvement during treatment for major depressive disorder. Psychiatry Res. 2011;192(3):188-94. 21546222 10.1016/j.pscychresns.2010.12.007 3152489
30. Hunter AM Korb AS Cook IA: Rostral anterior cingulate activity in major depressive disorder: state or trait marker of responsiveness to medication? J Neuropsychiatry Clin Neurosci. 2013;25(2):126-33. 23686030 10.1176/appi.neuropsych.11110330
31. Arns M Bruder G Hegerl U: EEG alpha asymmetry as a gender-specific predictor of outcome to acute treatment with different antidepressant medications in the randomized iSPOT-D study. Clin Neurophysiol. 2016;127(1):509-19. 26189209 10.1016/j.clinph.2015.05.032 F1000 Recommendation
32. Olbrich S Trankner A Surova G: CNS- and ANS-arousal predict response to antidepressant medication: Findings from the randomized iSPOT-D study. J Psychiatr Res. 2016;73:108-15. 26714202 10.1016/j.jpsychires.2015.12.001 F1000 Recommendation
33. Mulert C Juckel G Brunnmeier M: Prediction of treatment response in major depression: integration of concepts. J Affect Disord. 2007;98(3):215-25. 16996140 10.1016/j.jad.2006.07.021
34. Smeraldi E Zanardi R Benedetti F: Polymorphism within the promoter of the serotonin transporter gene and antidepressant efficacy of fluvoxamine. Mol Psychiatry. 1998;3(6):508-11. 9857976 10.1038/sj.mp.4000425
35. Pollock BG Ferrell RE Mulsant BH: Allelic variation in the serotonin transporter promoter affects onset of paroxetine treatment response in late-life depression. Neuropsychopharmacology. 2000;23(5):587-90. 11027924 10.1016/S0893-133X(00)00132-9
36. Lim SW Won HH Kim H: Genetic prediction of antidepressant drug response and nonresponse in Korean patients. PLoS One. 2014;9(9):e107098. 25226239 10.1371/journal.pone.0107098 4166419 F1000 Recommendation
37. Kautzky A Baldinger P Souery D: The combined effect of genetic polymorphisms and clinical parameters on treatment outcome in treatment-resistant depression. Eur Neuropsychopharmacol. 2015;25(4):441-53. 25769916 10.1016/j.euroneuro.2015.01.001 F1000 Recommendation
38. Lopez JP Lim R Cruceanu C: miR-1202 is a primate-specific and brain-enriched microRNA involved in major depression and antidepressant treatment. Nat Med. 2014;20(7):764-8. 24908571 10.1038/nm.3582 4087015 F1000 Recommendation
39. Pettai K Milani L Tammiste A: Whole-genome expression analysis reveals genes associated with treatment response to escitalopram in major depression. Eur Neuropsychopharmacol. 2016;26(9):1475-83. 27461515 10.1016/j.euroneuro.2016.06.007 F1000 Recommendation
40. Baudry A Mouillet-Richard S Launay JM: New views on antidepressant action. Curr Opin Neurobiol. 2011;21(6):858-65. 21530233 10.1016/j.conb.2011.03.005
41. Belzeaux R Lin CW Ding Y: Predisposition to treatment response in major depressive episode: A peripheral blood gene coexpression network analysis. J Psychiatr Res. 2016;81:119-26. 27438688 10.1016/j.jpsychires.2016.07.009 F1000 Recommendation
42. Gururajan A Naughton ME Scott KA: MicroRNAs as biomarkers for major depression: a role for let-7b and let-7c. Transl Psychiatry. 2016;6(8):e862. 27483380 10.1038/tp.2016.131 5022079 F1000 Recommendation
43. Thase ME: Using biomarkers to predict treatment response in major depressive disorder: evidence from past and present studies. Dialogues Clin Neurosci. 2014;16(4):539-44. 25733957 4336922
44. Uher R Tansey KE Dew T: An inflammatory biomarker as a differential predictor of outcome of depression treatment with escitalopram and nortriptyline. Am J Psychiatry. 2014;171(12):1278-86. 25017001 10.1176/appi.ajp.2014.14010094 F1000 Recommendation
45. Nase S Kohler S Jennebach J: Role of Serum Brain Derived Neurotrophic Factor and Central N-Acetylaspartate for Clinical Response under Antidepressive Pharmacotherapy. Neurosignals. 2016;24(1):1-14. 26859851 10.1159/000442607 F1000 Recommendation
46. Dreimuller N Schlicht KF Wagner S: Early reactions of brain-derived neurotrophic factor in plasma (pBDNF) and outcome to acute antidepressant treatment in patients with Major Depression. Neuropharmacology. 2012;62(1):264-9. 21803060 10.1016/j.neuropharm.2011.07.017